MassChallenge Startup Spotlight
METSYSTEM is proud to be part of the 2025 U.S. Early Stage Healthcare Cohort.
Our technology is taking the guesswork out of cancer treatment to personalize therapies.
As a MassChallenge member, we are accelerating our mission to deliver personalized treatment to every cancer patient — and we welcome collaborators and investors to join us.
Texas Medical Center Innovation Day
Watch our CTO and Co-founder, Kamilla, explain how METSYSTEM is transforming cancer treatment with personalized drug screening.
The video highlights the problem, our solution, and why we are seeking collaborators and investors.
Hello Tomorrow Presentation
At Hello Tomorrow, CAIO Silja presents how METSYSTEM is personalizing cancer care.
By growing each patient’s tumor tissue outside the body and applying AI-driven analysis, we help oncologists identify the most effective therapy.
We are proud to share our vision on the global stage and invite collaborators and investors to join us in bringing personalized treatment to every cancer patient.
Optimum Perspectives Podcast featuring Metsystem CEO Ninna Struck Rossen
International Day of Women & Girls in Science: Breaking barriers and channeling your inner cavewoman
In this Optimum Perspectives celebratory episode for International Day of Women & Girls in Science, hear from five influential women on how they broke down gender barriers to succeed in the life science industry.
See today’s investors signing the most cheques in European healthtech in 2023, according to Dealroom data
BII is a non-profit accelerator/incubator, backed by a €470m donation from the Novo Nordisk Foundation. It backs pre-seed and pre-investment startups, including disease diagnostics startup Rapidemic and cancer treatment platform Metsystem.
See today’s BioWorld MedTech
Metsystem receives injection of funds to validate cancer metastasis prognosis platform
MEDWATCH 22.3.2023
Entrepreneurs create prognosis service for hospitals: Will identify patients at high risk of metastases.
Newly founded Metsystem aims to make its prognosis service available in 2025 initially to hospitals in Denmark, but later abroad and to pharmaceutical companies as a test of their cancer treatment in the preclinical stage.
